Our research is focused on the long-term goal of evaluating the hypothesis that: An anti-tumor immunotherapeutic strategy that targets multiple tumor-associated antigens (TAAs) will be more efficacious than a strategy targeting a single TAA. Our immediate research efforts span studies of basic immunology to the development and in vivo evaluation of genetic immunotherapy strategies. The laboratory encompasses work focused upon dendritic cell (DC) biology in order to provide direction for the development of anti-tumor immunotherapeutic strategies with the best potential for eliciting efficacious anti-tumor immune responses. We study fundamental aspects of DC biology particularly as it pertains to DC activation and DC subset trafficking. We are pursuing two developmental immunotherapeutic strategies, "naked DNA" vaccine, making use of a novel vector we designed and constructed, and an alphavirus replicon vector system. All anti-tumor immunotherapeutic strategies are evaluated in rigorous rat syngeneic tumor models using rat neu, the homologue of human Her 2/neu, as a prototypical target antigen.
136 Sprague Hall